First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2016 Aug 13

PMID 27516450

Citations 57

Authors

Neeta Pandit-Taskar

Joseph A ODonoghue

Shutian Ruan

Serge K Lyashchenko

Jorge A Carrasquillo

Glenn Heller

Danny F Martinez

Sarah M Cheal

Jason S Lewis

Martin Fleisher

Jennifer S Keppler

Robert E Reiter

Anna M Wu

Wolfgang A Weber

Howard I Scher

Steven M Larson

Michael J Morris

Affiliations

Soon will be listed here.

Abstract

Methods: Patients received 185 MBq (5 mCi) of Zr-IAB2M and Df-IAB2M at total mass doses of 10 (n = 6), 20 (n = 6), and 50 mg (n = 6). Whole-body and serum clearance, normal-organ and lesion uptake, and radiation absorbed dose were estimated, and the effect of mass escalation was analyzed.

Results: Eighteen patients were injected and scanned without side effects. Whole-body clearance was monoexponential, with a median biologic half-life of 215 h, whereas serum clearance showed biexponential kinetics, with a median biologic half-life of 3.7 (12.3%/L) and 33.8 h (17.9%/L). The radiation absorbed dose estimates were 1.67, 1.36, and 0.32 mGy/MBq to liver, kidney, and marrow, respectively, with an effective dose of 0.41 mSv/MBq (1.5 rem/mCi). Both skeletal and nodal lesions were detected with Zr-IAB2M, most visualized by 48-h imaging.

Conclusion: Zr-IAB2M is safe and demonstrates favorable biodistribution and kinetics for targeting metastatic prostate cancer. Imaging with 10 mg of minibody mass provides optimal biodistribution, and imaging at 48 h after injection provides good lesion visualization. Assessment of lesion targeting is being studied in detail in an expansion cohort.

Citing Articles

Advances and challenges in immunoPET methodology.

Mohr P, van Sluis J, Lub-de Hooge M, Lammertsma A, Brouwers A, Tsoumpas C Front Nucl Med. 2024; 4:1360710.

PMID: 39355220 PMC: 11440922. DOI: 10.3389/fnume.2024.1360710.

Single Chelator-Minibody Theranostic Agents for Zr PET Imaging and Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.

Ho K, Tatum D, Watkinson L, Carmack T, Jia F, Mascioni A J Nucl Med. 2024; 65(9):1435-1442.

PMID: 39142831 PMC: 11372255. DOI: 10.2967/jnumed.124.267667.

PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?.

Sallam M, Nguyen N, Sainsbury F, Kimizuka N, Muyldermans S, Benesova-Schafer M Theranostics. 2024; 14(8):3043-3079.

PMID: 38855174 PMC: 11155394. DOI: 10.7150/thno.92612.

First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.

Hamdy F, Lamb A, Tullis I, Verrill C, Rombach I, Rao S Eur J Nucl Med Mol Imaging. 2024; 51(10):3009-3025.

PMID: 38853153 PMC: 11300503. DOI: 10.1007/s00259-024-06713-x.

Phenomic Imaging.

Lan L, Feng K, Wu Y, Zhang W, Wei L, Che H Phenomics. 2024; 3(6):597-612.

PMID: 38223684 PMC: 10781914. DOI: 10.1007/s43657-023-00128-8.

References

Holland J, Divilov V, Bander N, Smith-Jones P, Larson S, Lewis J . 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010; 51(8):1293-300. PMC: 2998794. DOI: 10.2967/jnumed.110.076174. View

Olafsen T, Betting D, Kenanova V, Salazar F, Clarke P, Said J . Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009; 50(9):1500-8. PMC: 2852538. DOI: 10.2967/jnumed.108.060426. View

Schauer U, Stemberg F, Rieger C, Borte M, Schubert S, Riedel F . IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. Clin Chem. 2003; 49(11):1924-9. DOI: 10.1373/clinchem.2003.022350. View

Vosjan M, Perk L, Visser G, Budde M, Jurek P, Kiefer G . Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010; 5(4):739-43. DOI: 10.1038/nprot.2010.13. View

Bander N, Milowsky M, Nanus D, Kostakoglu L, Vallabhajosula S, Goldsmith S . Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005; 23(21):4591-601. DOI: 10.1200/JCO.2005.05.160. View

Pandit-Taskar N, ODonoghue J, Beylergil V, Lyashchenko S, Ruan S, Solomon S . ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41(11):2093-105. PMC: 4404641. DOI: 10.1007/s00259-014-2830-7. View

Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill A . Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys. 2000; 27(9):2150-64. DOI: 10.1118/1.1288393. View

Wu A . Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2008; 50(1):2-5. DOI: 10.2967/jnumed.108.056887. View

Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr P . Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984; 72(1):77-89. DOI: 10.1016/0022-1759(84)90435-6. View

10.

Leyton J, Olafsen T, Lepin E, Hahm S, Bauer K, Reiter R . Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res. 2008; 14(22):7488-96. PMC: 2720761. DOI: 10.1158/1078-0432.CCR-07-5093. View

11.

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B . PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2012; 40(4):486-95. DOI: 10.1007/s00259-012-2298-2. View

12.

Wu A, Olafsen T . Antibodies for molecular imaging of cancer. Cancer J. 2008; 14(3):191-7. DOI: 10.1097/PPO.0b013e31817b07ae. View

13.

Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I . 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2011; 15(1):45-55. DOI: 10.1038/pcan.2011.35. View

14.

Morris M, Divgi C, Pandit-Taskar N, Batraki M, Warren N, Nacca A . Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005; 11(20):7454-61. DOI: 10.1158/1078-0432.CCR-05-0826. View

15.

Morgan D, Bray K . Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994; 26(4):292-307. DOI: 10.2165/00003088-199426040-00005. View

16.

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

17.

Olafsen T, Sirk S, Olma S, Shen C, Wu A . ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol. 2012; 33(3):669-77. DOI: 10.1007/s13277-012-0365-8. View

18.

Wong J, Chu D, Williams L, Yamauchi D, Ikle D, Kwok C . Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res. 2004; 10(15):5014-21. DOI: 10.1158/1078-0432.CCR-03-0576. View

19.

Viola-Villegas N, Sevak K, Carlin S, Doran M, Evans H, Bartlett D . Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm. 2014; 11(11):3965-73. PMC: 4224519. DOI: 10.1021/mp500164r. View

20.

Holland J, Sheh Y, Lewis J . Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009; 36(7):729-39. PMC: 2827875. DOI: 10.1016/j.nucmedbio.2009.05.007. View